Alzheimer’s Disease (AD) is a progressive neurodegenerative disorder. According to Suman Ray et al., 2023, it is the most common form of dementia, constituting approximately 75% of all dementia cases. The disease is characterized by memory loss, cognitive decline, and impaired daily functioning. Current therapies primarily focus on symptom management, but there is a growing focus on disease-modifying treatments targeting amyloid-beta, tau proteins, and neuroinflammation. According to the Alzheimer’s disease pipeline analysis by Expert Market Research, the market for AD therapeutics is expected to grow significantly in the coming years, driven by rising prevalence, an aging population, and increased research investment.
Major companies involved in the Alzheimer’s disease pipeline analysis include T3D Therapeutics, Inc., Cognition Therapeutics, and others.
Leading drugs currently in the pipeline include T3D-959, CT1812, THN391, and others.
The pipeline shows robust growth driven by an increasing focus on disease-modifying therapies, rising clinical trial activity in early-stage candidates, and advancements in targeted biologics and precision medicine approaches.
The Alzheimer’s Disease Pipeline Analysis Report by Expert Market Research gives comprehensive insights into Alzheimer’s disease therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for Alzheimer’s Disease. The Alzheimer’s disease report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The Alzheimer’s disease pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with Alzheimer’s disease treatment guidelines to ensure optimal care practices.
The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to Alzheimer’s disease.
Read more about this report - Request a Free Sample
Alzheimer’s disease is a progressive, irreversible brain disorder that impairs memory, thinking, and daily functioning. It occurs due to abnormal accumulation of amyloid beta plaques and tau tangles, leading to neuron loss and disrupted brain communication. Symptoms worsen over time, gradually reducing a person’s ability to carry out simple tasks, speak, and remember.
Alzheimer’s disease treatments focus on slowing cognitive decline, managing symptoms, and targeting disease pathology. Approved therapies include medications that reduce amyloid buildup, support neurotransmitter function, and improve daily living activities in affected patients. In May 2024, Kisunla (donanemab-azbt) received FDA approval for mild cognitive impairment and mild dementia stages of Alzheimer’s disease. Administered via intravenous infusion every four weeks, Kisunla demonstrated a significant reduction in amyloid levels and slowed clinical decline, representing a promising advancement in the Alzheimer’s disease drug pipeline.
The pipeline continues to expand as the global disease burden rises. According to Suman Ray et al., 2023, Alzheimer’s disease accounts for approximately 75% of all dementia cases, affecting over 57.4 million people worldwide. As per the Centers for Disease Control and Prevention (CDC), an estimated 6.7 million older adults in the United States have Alzheimer’s disease, expected to reach nearly 14 million by 2060. Miwa Ishihara et al., 2024, project that dementia cases in Japan will affect one-third of the population by 2060. Susan Scutti et al., 2023, highlight that over 75% of Alzheimer’s cases will occur in low- and middle-income countries by 2050. These trends underscore the urgent need for therapeutic advancements.
This section of the report covers the analysis of Alzheimer’s disease drug candidates based on several segmentations, including:
By Phase
The pipeline assessment report covers 50+ drug analyses based on phase:
By Drug Class
The Alzheimer’s disease pipeline analysis report covers 50+ drug analyses based on drug classes:
By Route of Administration
The pipeline assessment report covers 50+ drug analyses based on the route of administration.
The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to EMR analysis, phase II, with 43%, covers a major share of the total Alzheimer’s Disease clinical trials. It is followed by phase I at 25% and phase III at 21%. Strong representation across all phases indicates a robust pipeline, fostering innovation and potential new therapies that can enhance treatment options and market growth.
The drug molecule categories covered under the Alzheimer’s disease pipeline analysis include small molecules, monoclonal antibodies, and peptides. The Alzheimer’s disease report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for Alzheimer’s disease. Amyloid-targeting monoclonal antibodies are a major focus in the Alzheimer’s disease drug pipeline. For instance, trontinemab, an investigational monoclonal antibody, is under Phase Ib/IIa and upcoming Phase III studies for early symptomatic and preclinical Alzheimer’s disease. It works by clearing amyloid plaques in the brain, reducing tau pathology, and potentially delaying cognitive decline, while maintaining a favorable safety and tolerability profile.
The EMR report for the Alzheimer’s disease pipeline covers the profile of key companies involved in clinical trials and their drugs under development. It provides a detailed Alzheimer’s disease therapeutic assessment, analyzing the competitive dynamics of the clinical trial landscape. Below is the list of a few players involved in Alzheimer’s disease clinical trials:
This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for Alzheimer’s disease. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of Alzheimer’s disease drug candidates.
T3D-959, sponsored by T3D Therapeutics, Inc., is undergoing a Phase 2b/3 clinical study in patients with mild-to-moderate Alzheimer’s disease. This oral drug, administered once daily, is designed to activate PPAR delta and, to a lesser extent, PPAR gamma, regulating glucose and lipid metabolism in the brain. The study is evaluating its safety, efficacy, and potential disease-modifying effects compared to placebo over 78 weeks. The study is expected to be completed by June 2031.
CT1812, also known as Zervimesine, is an investigational oral therapy being developed by Cognition Therapeutics for the treatment of early Alzheimer's disease. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study is examining the safety, efficacy, and tolerability of two doses (100mg and 200mg) of CT1812 taken as two capsules orally once daily over approximately 18 months. CT1812 works by targeting toxic proteins Aβ and ɑ-synuclein in the brain, preventing neuronal damage and potentially slowing disease progression. The study is actively evaluating outcomes with an estimated completion in April 2027.
THN391, sponsored by Therini Bio, Inc., is a first-in-class humanized monoclonal antibody targeting fibrin-mediated neuroinflammation in Alzheimer’s disease. This Phase 1b study is evaluating the safety, tolerability, and pharmacokinetics of multiple ascending doses in patients with early Alzheimer’s disease. The drug is administered via three monthly clinic infusions, and the study is examining blood, MRI, spinal tap, neurological, and cognitive assessments over 6–8 months. THN391 works by selectively blocking fibrin-induced inflammation in the brain without affecting coagulation. The trial is expected to be completed by September 2026.
*Please note that this is only a partial list; the complete list of drugs will be available in the full report.*
The Alzheimer’s Disease Pipeline Analysis Report provides a strategic overview of the latest and future landscape of treatments for Alzheimer’s disease. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into Alzheimer’s disease collaborations, regulatory environments, and potential growth opportunities.
Upto 15% Off
USD
$1999 $1799
$3099 $2789
$4599 $3909
$5999 $5099
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
Explore our key highlights of the report and gain a concise overview of key findings, trends, and actionable insights that will empower your strategic decisions.
|
Scope of the Report |
Details |
|
Drug Pipeline by Clinical Trial Phase |
|
|
Route of Administration |
|
|
Drug Classes |
|
|
Leading Sponsors Covered |
|
|
Geographies Covered |
|
Mini Report
One User
USD 1,999
USD 1,799
tax inclusive*
Single User License
One User
USD 3,099
USD 2,789
tax inclusive*
Five User License
Five User
USD 4,599
USD 3,909
tax inclusive*
Corporate License
Unlimited Users
USD 5,999
USD 5,099
tax inclusive*
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Small Business Bundle
Growth Bundle
Enterprise Bundle
*Please note that the prices mentioned below are starting prices for each bundle type. Kindly contact our team for further details.*
Flash Bundle
Number of Reports: 3
20%
tax inclusive*
Small Business Bundle
Number of Reports: 5
25%
tax inclusive*
Growth Bundle
Number of Reports: 8
30%
tax inclusive*
Enterprise Bundle
Number of Reports: 10
35%
tax inclusive*
How To Order
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Share